mazdutide vs semaglutide (IBI362): The Next-Generation Dual GLP-1/Glucagon Agonist for Obesity and Metabolic Health Updates in Medicine | Mazdutide
Description
It was a 2X return on ad spend (ROAS) right out of the gate
Dysesthesia signal (Phase 3) TRIUMPH-4 topline results, released December 11, 2025, reported dysesthesia in about 20.9% of participants at the highest dose
To address these issues, two orally available GLP-1 RAs are currently in clinical trials
Novo Nordisks share price is down 54% from its peak in June 2024
Such understanding could help in addressing the barriers to continued use of these medications
